转移性乳腺癌是难以治疗，几乎总是致命的。
Metastatic breast cancers are hard to treat and almost always fatal.
新指南将总结关于晚期转移性乳腺癌的推荐方案。
The guidelines will summarize recommendations for advanced metastatic breast cancer.
在缺乏这些相互作用时转移性乳腺癌细胞应能生存。
Metastatic breast cancer cells must survive in the absence of these interactions.
该发现为针对转移性乳腺癌治疗进行一系列新的研究打开了道路。
This finding opens the way to new lines of research aimed at developing treatments for metastatic breast cancer.
非转移性乳腺癌细胞依靠与其他细胞和细胞外基质相互作用而生存。
Non-metastatic breast cancer cells rely on interactions with other cells and the extracellular matrix to survive.
方法2 1例病理确诊的晚期转移性乳腺癌，给予紫杉醇联合方案治疗。
Methods 21 pathologically and cytologically proved that the cases of breast cancer were treated with Paclitaxel plus DDP.
我们开发并描述了一个临床前的模型，用来评估免疫介导转移性乳腺癌疗法。
We have developed and characterized a preclinical model for the evaluation of immune-mediated metastatic breast cancer therapies.
目的研究单药多烯紫杉醇每周方案及每3周方案治疗转移性乳腺癌的疗效与毒性。
Objective To compare the efficacy and toxicity of docetaxel as a single agent for treating metastatic breast cancer with weekly and 3 weekly scheme.
HER2的异质性会影响HER 2阳性转移性乳腺癌患者曲妥珠单抗的效果和生存期。
HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer.
前期的研究包括转移性乳腺癌患者，蛋白结合型紫杉醇在抗肿瘤作用比单纯的紫杉醇溶剂要强。
In prior research involving metastatic breast cancer patients, nab-paclitaxel had produced significantly higher anti-tumor activity than solvent-based paclitaxel.
转移性乳腺癌并不经常是首次诊断，它只占新发病例的约10%，Cardoso医生解释说。
Metastatic breast cancer is not the initial diagnosis very often; it accounts for only about 10% of new cases, Dr. Cardoso explained.
结论：可治疗的体格缺陷是普遍的，广泛存在于转移性乳腺癌患者中，更大程度上见于门诊病人。
Conclusion: Remediable physical impairments were prevalent and poorly addressed among patients with metastatic breast cancer, drastically so in the outpatient setting.
背景与目的：晚期转移性乳腺癌的治疗较为困难，治疗的主要目的为缓解症状，延长高质量的生存期。
Background and purpose: the treatment of advanced metastatic breast cancer is very difficult. The main purpose of the treatment is to alleviate symptoms and prolong quality survival.
紫杉醇与S-1作为转移性乳腺癌的一线化疗（选择BC）：一项开放标签、非劣效性、随机3期试验。
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
从早期乳腺癌的治疗我们得知，使用国际性指南能改善患者生存——现在我们必须对转移性乳腺癌也这样做。
"We know from early-stage breast cancer that survival has improved with the use of international consensus guidelines - and now we must do the same for metastatic disease," she said.
“如果要实现任何新的疗法是治疗转移性乳腺癌，它是一个很长的时间-如果-我们就可以看到它，”马克曼说。
"If the goal of any new therapy is to cure metastatic breast cancer, it is going to be a very long time - if ever - before we see it," Markman said.
我们调查了HER 2异质性对112例her 2阳性转移性乳腺癌患者的曲妥珠单抗疗效和临床预后的影响。
We investigated the impact of HER2 heterogeneity on trastuzumab responses and clinical outcomes in 112 patients with HER2-positive metastatic breast cancer.
2011年11月23日——晚期乳腺癌特别是转移性乳腺癌治疗的新指南，已经由一个国际乳腺癌专家小组制订完成。
November 23, 2011 — New guidelines for the treatment of advanced breast cancer, specifically metastatic breast cancer, have been developed by an international group of breast cancer experts.
腋窝转移性淋巴结是乳腺癌的间接征象。
目的观察希罗达治疗转移性或复发性乳腺癌的疗效及不良反应。
Objective To evaluate the response rate and adverse reaction of metastatic and recurrent breast cancer patients treated with xeloda.
BSI的- 201目前正处于第二阶段的审判，并表示治疗转移性三阴性乳腺癌，卵巢癌和其他恶性肿瘤。
BSI-201 is currently in phase-two trials and is indicated for treatment of metastatic triple negative breast cancer, ovarian cancer and other malignancies.
BSI的- 201目前正处于第二阶段的审判，并表示治疗转移性三阴性乳腺癌，卵巢癌和其他恶性肿瘤。
BSI-201 is currently in phase-two trials and is indicated for treatment of metastatic triple negative breast cancer, ovarian cancer and other malignancies.
应用推荐